Liquidity and Capital Resources
Until the consummation of the Initial Public Offering, our only source of liquidity was an initial purchase of founder shares by our Sponsor, for $25,000 and loans from our Sponsor.
On November 2, 2021, we consummated our Initial Public Offering of 25,000,000 Units, at $10.00 per Unit, generating gross proceeds of $250,000,000. On November 12, 2021, the underwriters of the Initial Public Offering partially exercised their over-allotment option and on November 17, 2021, purchased an additional 1,377,660 Units (the “Over-Allotment Units”), generating gross proceeds of $13,776,600.
Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 8,150,000 private placement warrants (“Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to our sponsor, generating gross proceeds of $8,150,000.
Simultaneously with the closing of the exercise of the over-allotment option, the Company consummated the sale of 275,532 additional Private Placement Warrants (the “Over-Allotment Warrants”) at a price of $1.00 per warrant in a private placement to our sponsor, generating gross proceeds of $275,532.
A total of $263,776,600 of the proceeds of the sale of the Units in the Initial Public Offering, the Over-Allotment Units, the Over-Allotment Warrants and the Private Placement Warrants were placed in the Trust Account at J.P. Morgan Chase Bank, N.A. maintained by Continental Stock Transfer & Trust Company, acting as trustee.
For the year ended December 31, 2022, net cash used in operating activities was $978,399, which was primarily due to operational costs paid during the period.
For the period from February 10, 2021 (inception) through December 31, 2021, net cash used in operating activities was $886,922, which was primarily due to operational and formation costs paid during the period.
There were no cash flows from investing activities for the year ended December 31, 2022.
For the period from February 10, 2021 (inception) through December 31, 2021, net cash used in investing activities of $263,776,600 was the result of the amount of net proceeds from the Initial Public Offering and the partial exercise of the over-allotment option being deposited to the Trust Account.
There were no cash flows from financing activities for the year ended December 31, 2022.
For the period from February 10, 2021 (inception) through December 31, 2021, net cash provided by financing activities of $266,157,455 was comprised of $258,501,068 in proceeds from the issuance of units in the Initial Public Offering and the partial exercise of the over-allotment option, net of underwriter’s discounts paid, $8,425,532 in proceeds from the issuance of warrants in a private placement to our sponsor, reimbursement of offering costs from the underwriters’ pursuant to the agreement letter of $527,553, proceeds from the promissory note—related party of $298,629 and proceeds from the sale of Class B ordinary shares to our sponsor of $25,000, offset in part by the payment of $1,321,698 for offering costs associated with the Initial Public Offering and repayment of the outstanding balance on the promissory note to our sponsor of $298,629.
As of December 31, 2022, we had marketable securities held in the Trust Account of $267,475,787 consisting of money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury.
As of December 31, 2022, we had cash of $515,534 held outside the Trust Account and a working capital surplus of $141,303. We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a business combination.